Piramal Pharma Diversifies Supply Chain, Bets on CDMO for Growth
Piramal Pharma is cutting its reliance on Chinese raw materials to a single-digit procurement share, de-risking its supply chain.

Piramal Pharma is reducing its reliance on Chinese raw materials and expanding manufacturing across India, the UK, and the US to mitigate geopolitical risks. The company has cut its dependence on Chinese raw materials to a single-digit share of its consolidated procurement spending, a move aimed squarely at managing supply-chain risks rather than seeking commercial advantage.
This strategic diversification spreads procurement and manufacturing operations across multiple geographies. By building resilience into its supply chain, the company is insulating itself from potential disruptions and positioning for steadier growth.
CDMO as Growth Engine
Piramal Pharma expects its Contract Development and Manufacturing Organization business to be the biggest driver of revenue and margin growth over the next two to three years. This global segment is central to the company's future growth strategy, with its performance set to outpace other divisions. The focus on CDMO services aligns with broader industry demand for outsourced pharmaceutical manufacturing and development expertise.
Margin Advantage from Specialized Manufacturing
The company's international manufacturing facilities, which produce specialized and complex products, generate better gross margins than its sites in India. This margin advantage stems from the advanced and technically demanding nature of the work conducted at these global plants.
These specialized offerings, including ADCs, HPAPIs, and sterile injectables, command premium pricing and are less susceptible to commoditized price competition. The international network, spanning India, the UK, and the US, provides the technological backbone for this high-margin work.
Consumer Healthcare Transition
Piramal Pharma's consumer healthcare segment is shifting its focus to proprietary brands. This transition comes ahead of the expiry of its distribution agreement with Bayer in December. While that agreement contributed 475 crore rupees to the current fiscal year's revenue, it is a low-margin business. The company does not expect the exit of this distribution deal to materially affect its overall financial performance. The strategic pivot aims to build a more owned and potentially more profitable brand portfolio in the consumer health space.
The company is now looking to the expansion of complex peptides manufacturing as the next frontier for growth, building on its established expertise in specialized drug production.





